Home › Companies › VOR

Vor Biopharma

Market cap $1.12B 61.4M shares (10-Q, Oct 26, 2026) × $18.18 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. telitacicept Ph3 topline1H 2027telitacicept Ph3 topline, 1H 2027, thesis-defining
  2. UPSTREAM MG Ph3 topline1H 2027UPSTREAM MG Ph3 topline, 1H 2027, major
  3. RemeGen warrants FDA approval~1Q 2027RemeGen warrants FDA approval, ~1Q 2027, material
  4. RC298 IND filing1H 2027RC298 IND filing, 1H 2027, notable
  5. UPSTREAM oMG pivotal start1H 2027UPSTREAM oMG pivotal start, 1H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Discontinued (4)

Capital (as filed)

Cash
$79.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$403M Sep 30, 2026
Operating cash flow
−$32.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$482M cash, runway early 2029 per the update of Oct 30, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Vor Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Vor Bio (VOR) - Scientific Deep Dive Fortelitacicept and Pipeline Products Telitacicept's dual BAFF/APRIL biology is compelling but the 2028 composition-of-matter patent cliff, CMC tech transfer risk, and demographic translation uncertainty warrant waiting for enrollment and manufacturing clarity before committing capital.
  2. Watch UPDATE: Vor Bio (VOR) - The Anchor is Selling RA Capital's aggressive selling of directly-held common stock muddies the conviction signal without changing the underlying science or cash thesis, warranting continued caution on the sidelines.
  3. Speculative buy speculative UPDATE: Vor Bio (VOR) - NEJM Stamps the Free Look NEJM publication of TELIGAN Phase 3 IgAN data with 55% placebo-adjusted proteinuria reduction and eGFR preservation materially de-risks the dual BAFF/APRIL biology and upgrades the pipeline-in-a-product narrative from marketing to investable.
  4. Speculative buy speculative UPDATE: Vor Bio (VOR) - The Free Look Pays Off Twice Two simultaneous NMPA approvals (IgAN and SjD) give telitacicept five approved indications in China, with SjD being the first approved systemic therapy globally, further compounding biological and regulatory de-risking while the price has weakened.
  5. Speculative buy speculative UPDATE: Vor Bio (VOR) - The Anchor Leaves, the Closer Arrives Levin's board resignation removes the last governance signal of RA Capital's commitment, but Zaccardelli's appointment — a CEO with three strategic exits including a $10B Merck deal — sharpens the M&A exit optionality and adds manufacturing expertise to address the CMC silent-killer risk.
  6. Speculative buy speculative UPDATE: Vor Bio (VOR) - RA Answers the Watch Item RA Capital's cashless exercise of 2.1M pre-funded warrants into common stock is the opposite of walking off the field, shifting the RA read from bearish-at-governance-level to ambiguous and modestly constructive.
  7. Speculative buy speculative UPDATE: Vor Bio (VOR) - They Sold Into the Rip Management's $48.9M ATM raise at $19.11 confirms dilution appetite rather than a dilution gap, while enrollment remains on track for 1H27 and commercial build-out spending signals a credible launch-or-sell narrative ahead of the binary.
  8. Speculative buy speculative UPDATE: Vor Bio (VOR) - The Enrollment Clock Stops UPSTREAM MG is fully enrolled and the 1H27 topline is now arithmetic rather than guidance, retiring enrollment slippage risk while the demographic translation question — whether a -4.8 MG-ADL delta from Chinese patients replicates in Western populations — remains entirely unanswered.
  9. Speculative buy speculative UPDATE: Vor Bio (VOR) - The Kidney Clock Nearly Stops Two-year TELIGAN eGFR slope data (-0.6 vs -5.7 mL/min/1.73m²/year, p<0.001) converts the proteinuria surrogate win into hard organ-function proof, delivering the strongest biological validation yet while the stock has pulled back 24.5% from its September high.
  10. Speculative buy speculative UPDATE: Vor Bio (VOR) - The ATM Gets Reloaded A new $150M ATM facility confirms management's willingness to sell paper into strength ahead of the 1H27 binary, creating a supply overhang that could cap rallies, though the balance sheet doesn't need the cash and the clinical timeline remains locked.
  11. Speculative buy speculative UPDATE: Vor Bio (VOR) - Buying the Sequel Before the Premiere Vor's ~$56M acquisition of RC298, a preclinical long-acting TACI-Fc successor, is a credibly priced option on the 2028 patent cliff problem, but the asset is years from proof and every new program depends on telitacicept winning in UPSTREAM MG.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (35)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

19 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)